Search research articles
Contact Us
Filters
Showing results (51-60 of 72) with videos related to
Page
of 8
Sort By:
Frontiers in Immunology
|
July 26, 2021
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia
Annika Nelde, Yacine Maringer, Tatjana Bilich, et al.
Science Translational Medicine
|
March 16, 2021
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
Tatjana Bilich, Annika Nelde, Jonas S Heitmann, et al.
Frontiers in Oncology
|
April 12, 2024
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
Christopher Hackenbruch, Jens Bauer, Jonas S Heitmann, et al.
International Journal of Molecular Sciences
|
April 13, 2024
Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome
Anna Seller, Christian M Tegeler, Jonas Mauermann, et al.
Journal for Immunotherapy of Cancer
|
April 15, 2025
PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
Steffen Lemke, Marissa L Dubbelaar, Patrick Zimmermann, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2022
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
Naveen K Mehta, Martin Pfluegler, Kristan Meetze, et al.
Journal of Hematology & Oncology
|
August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Jonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Nature Communications
|
October 4, 2017
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia
Melanie Märklin, Jonas S Heitmann, Alexander R Fuchs, et al.
Cancer Discovery
|
May 20, 2021
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Tatjana Bilich, Malte Roerden, Yacine Maringer, et al.
EMBO Molecular Medicine
|
December 29, 2020
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer
Latifa Zekri, Fabian Vogt, Lukas Osburg, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 72) with videos related to
Sort By:
Page
of 8
Frontiers in Immunology
|
July 26, 2021
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia
Annika Nelde, Yacine Maringer, Tatjana Bilich, et al.
Science Translational Medicine
|
March 16, 2021
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
Tatjana Bilich, Annika Nelde, Jonas S Heitmann, et al.
Frontiers in Oncology
|
April 12, 2024
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
Christopher Hackenbruch, Jens Bauer, Jonas S Heitmann, et al.
International Journal of Molecular Sciences
|
April 13, 2024
Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome
Anna Seller, Christian M Tegeler, Jonas Mauermann, et al.
Journal for Immunotherapy of Cancer
|
April 15, 2025
PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
Steffen Lemke, Marissa L Dubbelaar, Patrick Zimmermann, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2022
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
Naveen K Mehta, Martin Pfluegler, Kristan Meetze, et al.
Journal of Hematology & Oncology
|
August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Jonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Nature Communications
|
October 4, 2017
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia
Melanie Märklin, Jonas S Heitmann, Alexander R Fuchs, et al.
Cancer Discovery
|
May 20, 2021
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Tatjana Bilich, Malte Roerden, Yacine Maringer, et al.
EMBO Molecular Medicine
|
December 29, 2020
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer
Latifa Zekri, Fabian Vogt, Lukas Osburg, et al.
Page
of 8